by Brenda Baletti, Ph.D., Childrens Health Defense:

The vaccine, Cyfendus, is approved for use after suspected or confirmed exposure to Bacillus anthracis, also known as anthrax, but must be administered together with other antibacterial drugs.

The U.S. Food and Drug Administration (FDA) on Thursday approved an anthrax vaccine for adults ages 18-65, according to Emergent BioSolutions, the vaccine’s maker.

The vaccine, Cyfendus, is approved for use after suspected or confirmed exposure to Bacillus anthracis, also known as anthrax, but must be administered together with other antibacterial drugs, Reuters reported.